Amgen Announces Tezepelumab Biologics License Application Submitted To U.S. FDA

THOUSAND OAKS, Calif., May 10, 2021 —Amgen (NASDAQ: AMGN) today announced its partner AstraZeneca (NASDAQ: AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma. The submission is supported by positive clinical trial results from the PATHFINDER clinical program including the pivotal NAVIGATOR Phase 3 trial; demonstrating a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate (AAER) in patients with severe, uncontrolled asthma compared to placebo.1 Tezepelumab is the only biologic to consistently and significantly reduce AAER in a broad population of severe asthma patients irrespective of the baseline eosinophil counts across Phase 2 and Phase 3 clinical trials. READ MORE